Log In
BCIQ
Print this Print this
 

CNTO 7160

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
Description mAb targeting interleukin-1 (IL-1) receptor-like 1 (IL1RL1; ST2; IL-33R)
Molecular Target Interleukin-1 (IL-1) receptor-like 1 (IL1RL1) (ST2) (IL-33R)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$229.7M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/27/2016

$229.7M

Undisclosed

Undisclosed

Get a free BioCentury trial today